Point72 Europe (London) LLP Verona Pharma PLC Transaction History
Point72 Europe (London) LLP
- $1.62 Billion
- Q4 2024
A detailed history of Point72 Europe (London) LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Point72 Europe (London) LLP holds 39,369 shares of VRNA stock, worth $2.52 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
39,369Holding current value
$2.52 Million% of portfolio
0.11%Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
217Shares Held
70.5MCall Options Held
1.4MPut Options Held
299K-
Perceptive Advisors LLC New York, NY6.39MShares$409 Million9.9% of portfolio
-
Nea Management Company, LLC Timonium, MD5.58MShares$357 Million18.53% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$217 Million9.42% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.13MShares$200 Million2.79% of portfolio
-
Lee Ainslie Maverick Capital LTD | Dallas, Tx3.13MShares$200 Million2.81% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $3.9B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...